The association between EGFR mutation status and atezolizumab therapy response should be explored, and further studies of these mechanisms are needed to effectively predict survival and to provide a better personalized treatment for individuals with EGFR mutations in NSCLC. Here, EGFR is linked to non-small cell lung carcinoma.